Providing patient-centered education and navigation support significantly increases consent rates for genomic testing, making ...

A nationwide Australian pilot screened more than 10,000 adults aged 18–40 years for high-risk genetic variants linked to ...

Genetic testing identifies germline mutations, while genomic testing analyzes somatic mutations in tumors, influencing treatment options. Broader testing criteria are expanding access to genetic ...

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials ASCO Guidelines provide recommendations with comprehensive ...

Leading genomic health experts from Monash University are calling for urgent government funding to progress the development ...

Tens of thousands of patients with lung cancer in the United Kingdom are missing out on targeted treatment that could improve their prognosis due to delays in genomic testing, a new report has warned.

For the more than 300,000 women diagnosed with breast cancer each year, one of the biggest challenges is uncertainty around treatment options. Treatment isn’t one-size-fits-all and often comes with ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...

Medicare-eligible patients with advanced cancers will have access to genomic tests under a national coverage determination CMS finalized March 16. The determination covers next-generation sequencing ...

FDA approves Guardant Health's blood test to help identify metastatic colorectal cancer patients eligible for targeted ...

The program enlists new technology that captures and preserves tumor cells typically discarded during routine biopsy ...

Leading genomic health experts from Monash University are calling for urgent government funding to progress the development of a national preventive genomic testing program that would save thousands ...